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8234 A NEWER CLASS III AGENT: ELECTROPHYSIOLOGIC EFFECTS 
IN VIVO AND IN VITRO -m -- 
Henry J. Duff, Elaine Brown, Wang Li, University of 
Calgary, Alberta, Canada 
8234 is an investigational compound vhich prolongs 
q onophasic action potential duration in vitro. The 
purpose of this study was to assess the antiarrhythmic 
activity of H234, in vivo, in a model of sustained 
ventricular tachycardia induced late folloving infarc- 
tion. ii234 suppressed inducible sustained ventricular 
tachycardia in 3 of 12 dogs at concentrations of H234 
vhich are being used in phase II clinical trials. This 
efficacy vas associated vith prolongation of ventricular 
refractoriness and electrogram QT diffusely through out 
the myocardium. Placebo produced no efficacy in 11 
dogs. H234 did not effect ventricular conduction time 
or pacing threshold. To assess the potential of H234 to 
produce proarrhythmia 3--700 fold higher doses of H234 
vere infused in dogs. At 200 fold high doses no ad- 
verse effects occurred, hovever at 700 fold higher doses 
1 of 5 dogs developed sinus arrest and asystole. No 
animal developed Torsade de pointes ventricular 
tachycardia. Conventional microelectrode studies in 
rabbit papillary muscle confirm that R234 (200 nH) 
prolonged action potential duration (90%) from 145k17 to 
172i21 ms without effects on Vmax of phase zero or 
resting membrane potential. 
The class III electrophysiologic effect of 8234, is 
associated vith antiarrhythmic activity vithout detec- 
table evidence of proarrhythmia in dog. 
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(Group A) had persistent but slower VT (256f19 to 351225 
msec) while 5 had no inducible VT (Group 8). The fQRS 
was longer in Group A than Group B at baseline (13524 va 
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prolongation of both fQRS (2535 vs 922 msec*) and LAS 
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between groups (baseline or after AA drug). Conclusion: 
Patients with VT who respond completely to Type I AA 
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Beta-adrenergic stimulation with isoproterenol or 
epinephrine has been demonstrated to antagonize the ther- 
apeutic effect of antiarrhythmic drugs in pts with Wolff- 
Parkinson-White syndrome (WPW), but the persistence of 
propafenone (P) efficacy in relation to poor-P (PPM) or 
extensive-P (EPM) metabolirers during a more physiologic 
situation such as ergometer test is unknown. Therefore, 
36 symptomatic pts with WPW underwent a combined ergome- 
ter test and transesophageal stimulation in order to in- 
duce atria1 fibrillation (AF) at rest (Re) and peak exer- 
cise (Ex) at the end of a week of treatment with P (900 
m /day) or placebo (Pla) given in double-blind mode. 
E 9 ght pts (24%) were identified as PPM by debrisoquine 
test, AF inducibility (Ind), AF duration (Dur), and mean 
RR interval during AF (xRR; msec) was considered. 
PLACEBO 
PPM EPM 
PROPAFENONE 
PPM EPM 
Ind Re 8(100%) 27( 96%) O( 0%) 8(29%)#* 
Ind Ex 8(100%) 28(100%) 
Dur 30 set Re 7( 88%) 23( 85%) 
Dur 30 set Ex B(lOO%) 28(100%) 
xRR stress Re 347+55 341+55 -349 368+40 
xRR stress Ex 323T41 320743 276 331T38 
Up 0.001 Pla vs P; $ij 0.001 Pm vs EPM; *p 0.05 Re-vs Ex. 
No difference in mean work load was found between the 
two regimens and between EPM and PPM. 
In conclusion, the data of this study indicate a re- 
versibility of P efficacy during the ergometer test with 
significant difference between PPM and EPM in controlling 
the heart rate during AF in pts with WPW. 
